Region — US. Neutral scientific reference — not offered for sale here.
Set region
Vallydia
ExploreShopToolsJournalTrustSearch ⌕
Explore  /  SS-31 (Elamipretide)
Research reference — not for sale

SS-31 (Elamipretide)

A
lead outcome
Barth syndrome — muscle strength (the…
grades vary by outcome ↓
Peptide
also called — SS-31 · Elamipretide (INN, the approved-drug name) · Bendavia (the name used in the cardiac-ischemia trials) · MTP-131 · trade name Forzinity (FDA-approved formulation) · sequence D-Arg-2,6-dimethyltyrosine-Lys-Phe-NH₂. INCI: none
mitochondrial(approved:) Barth-syndrome muscle strength(research/failed:) heart failurecellular energy / "anti-aging."

The mitochondrial anchor — and the register's cleanest "approved vs failed" split on one page. Three honest points define this entry: (1) as of September 2025 it is FDA-approved (Forzinity) for one ultra-rare disease — the first-ever approved therapy for a mitochondrial disease; (2) for the popular

In brief

SS-31 (elamipretide) is a mitochondria-targeting tetrapeptide that binds cardiolipin and stabilises the inner-membrane machinery that produces cellular energy. In September 2025 it became the first FDA-approved therapy for a mitochondrial disease — Barth syndrome — where a Phase 3 trial's open-label extension and a natural-history comparison showed improved muscle strength, walk distance and cardiac stroke volume over ~48 weeks. Crucially, its trials in the conditions people popularly associate it with have a much weaker record: the pivotal Barth randomized crossover phase and the primary mitochondrial myopathy Phase 3 both missed their primary endpoints, the heart-failure (HFpEF) program improved mitochondrial bioenergetics without functional benefit, and dry AMD results were mixed/negative. The "cellular energy / anti-aging" story rests almost entirely on aged-mouse studies, not human data.

Legal standing, by region
International
investigational outside the US Barth indication

investigational outside the US Barth indication.

Evidence, by outcome

An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.

OutcomeEvidence base · effectGrade
Barth syndrome — muscle strength (the approved use)
Approved, but for an ultra-rare disease (~1 in 300,000–500,000 births); accelerated approval → confirmatory trial still owed; the randomized phase actually missed its primary endpoint — approval leaned on the extension + intermediate endpoint
Phase 3 (TAZPOWER) crossover + open-label extension + natural-history comparison (Hornby 2022); ~48-wk gains in 6-min walk, symptom scale, cardiac stroke volume → FDA accelerated approval Sep 2025
A
Primary mitochondrial myopathy
The pivotal trial for the "mito myopathy" use failed; a short earlier study (5-day) had shown a walk-distance signal that didn't hold up
MMPOWER-3 Phase 3 — did NOT meet primary endpoints (6-min walk, symptom score) in the overall population
F
Heart failure (HFpEF / cardiac)
"Fixed the chemistry, didn't move the patient" — a recurring theme; long-term HFpEF trials did not translate mechanism into outcomes
Multiple Phase 2 trials (Bendavia/elamipretide; Daubert 2017) — improved myocardial bioenergetics but no functional/clinical benefit
F
Dry age-related macular degeneration (AMD)
Some exploratory signals; did not establish efficacy
Phase 2 (ReCLAIM) — mixed/negative on primary endpoints
D
Acute kidney injury / ischemia-reperfusion
Strong animal data (kidney protection sustained months after dosing); human efficacy not established
Preclinical + early clinical
D
"Cellular energy / anti-aging / exercise capacity in healthy people" (the popular use)
The headline longevity claim is animal-only; not demonstrated in healthy humans. This is what most gray-market buyers want it for — and it's the weakest-evidenced use
Aged-mouse studies (Siegel 2013; Campbell 2019 — restored redox balance, improved exercise tolerance in old mice)
F
Cognitive / neuroprotection
Improves mitochondrial/synaptic health in rodent models; not confirmed in humans
Preclinical models only
F
Safety
Generally well tolerated; most common AE is injection-site reaction; rare serious hypersensitivity reactions possible (per FDA label); water-soluble, renally excreted
FDA trial program + Phase 2 across indications

Identity a synthetic tetrapeptide (4 amino acids, < 40 aa → peptide) that carries a positive charge and readily crosses cell membranes to concentrate ~1,000–5,000× inside mitochondria, where it binds the unique inner-membrane phospholipid cardiolipin. One of the most-studied mitochondria-targeting compounds in existence. ## Mechanism (as proposed) SS-31 is a cell-penetrating tetrapeptide that accumulates in mitochondria and binds cardiolipin on the inner mitochondrial membrane. By stabilising cardiolipin, it props up the respiratory-chain supercomplexes (the assembled Complexes I–IV), improving electron-transport efficiency and ATP production while lowering reactive-oxygen-species leak. In Barth syndrome — an X-linked disease where tafazzin mutations cripple cardiolipin remodeling — this directly addresses the molecular root. The exact downstream mechanism beyond cardiolipin binding "remains unclear" (its own mechanistic literature says so), which is part of why it works in the disease built on cardiolipin but repeatedly failed in messier, multifactorial diseases like heart failure.

Sources — 5 cited
01FDA. FDA Grants Accelerated Approval to First Treatment for Barth Syndrome (Forzinity/elamipretide). Sept 19, 2025; FDA Integrated Review, NDA 215244.
02Reid Thompson W, et al. Phase 2/3 randomized trial + open-label extension of elamipretide in Barth syndrome. Genet Med. 2021; Hornby B, et al. Natural-history comparison. Orphanet J Rare Dis. 2022.
03Daubert MA, et al. Novel mitochondria-targeting peptide in heart failure: randomized placebo-controlled trial of elamipretide. Circ Heart Fail. 2017.
04Siegel MP, et al. Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal-muscle performance in aged mice. Aging Cell. 2013; Campbell MD, et al. Free Radic Biol Med. 2019.
05Elamipretide mechanistic review — first cardiolipin-directed mitochondrial therapeutic approved under accelerated approval. Drug Discov Ther. 2026.
Review status
Not yet reviewed

A credentialed reviewer (PharmD / PhD / MD) will be named before this entry is finalised. Until then, treat it as a working draft. Last updated July 2026 (status evolving — accelerated approval requires a confirmatory trial; re-check the confirmatory-trial outcome and any label expansion).

Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.

Related compounds
MOTS-cC
Peptide
Humanin (HN / HNG / S14G-Humanin)C
Peptide
Explore by goal
Longevity & cellularMitochondrial
Vallydia

A neutral reference and a lawful-lane shop. Registered in Spain. Information for those who seek it — never promotion.

Region — United States
ExploreRegisterCategoriesTrust & COA
ShopCosmetic peptidesJournal
TermsPrivacyCookiesReturnsShippingImprint

This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia SL — Registered in Spain.

SS-31 (Elamipretide) — approved for Barth, failed for heart failure: the honest evidence · Vallydia